Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06500637 · ClinicalTrials.gov registry record · Phase 2
TB006 for Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder, sponsored by Rossignol Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT06500637: Recruiting Phase 2 study of Autism Spectrum Disorder, sponsored by Rossignol Medical Center.
NCT06500637 is a Phase 2 study of Autism Spectrum Disorder that is actively recruiting participants, run by Rossignol Medical Center. The registered enrollment target is 45 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06500637, a Phase 2 study of Autism Spectrum Disorder, is actively recruiting participants, sponsored by Rossignol Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
Primary Outcome
The CARS is a measure of autism severity completed by a clinician. Lower Score is Better. Scores range from 15 to 60.
Conditions Studied
Interventions
- DRUG TB006
Study Locations (2)
Arizona
- Rossignol Medical Center - Phoenix
California
- Rossignol Medical Center - Aliso Viejo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-08-03 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What NCT06500637 shows while recruiting
NCT06500637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which TB006 is the first listed.
NCT06500637 reports a single indexed study location in Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06500637 about?
NCT06500637 is a clinical study titled "TB006 for Autism Spectrum Disorder". Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or plac...
What is the current status of trial NCT06500637?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-08-03. Estimated completion is 2026-07-31.
What conditions does trial NCT06500637 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT06500637?
The interventions under investigation include: TB006 (DRUG).
Who is sponsoring clinical trial NCT06500637?
This trial is sponsored by Rossignol Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06500637 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06500637's enrollment target sits among peer trials
45 150th of 224 higher than 75 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI